

**Adrenal function in hospitalised patients with pulmonary
tuberculosis treated with rifampicin**

Willem Daniel Francois Venter

A research report submitted to the Faculty of Health Sciences, University of
Witwatersrand, in partial fulfillment of the requirements for the degree of
Master of Medicine in the branch of Internal Medicine

Johannesburg 2008

Declaration

I, Willem Daniel Francois Venter, declare that this research report is my own work. It is being submitted for the degree of Master of Medicine in the clinical discipline of Internal Medicine in the University of the Witwatersrand, Johannesburg. It has not been submitted before for any degree or examination at this or any other University.

Signature: _____

_____ day of _____, 2008.

Dedication

Dedicated to all my medical teachers who have taken time and patience to educate me about our discipline.

Publication and presentations arising from this study

Venter WDF, Panz VR, Feldman C, Joffe BI, Adrenocortical function in hospitalised patients with pulmonary tuberculosis receiving a rifampicin-based regimen – a pilot study. South African Medical Journal 2006; 96; (1); 62-67

Venter WDF, Panz VR, Feldman C, Joffe BI, Adrenocortical function in hospitalised patients with pulmonary tuberculosis receiving a rifampicin-based regimen. Poster presentation, Society of Endocrinology, Metabolism and Diabetes of South Africa, Johannesburg, 9-12 April, 2005

Abstract from the conference published in Journal of Endocrinology, Metabolism and Diabetes of South Africa 2005; 10 (1), 37

Abstract

Introduction: Tuberculosis carries a high mortality in the days immediately after treatment. It is also the commonest cause of adrenal insufficiency in the developing world. Rifampicin is a potent hepatic enzyme inducer, and may contribute to adrenal insufficiency by accelerating cortisol breakdown. The aim of the study was to determine whether rifampicin induced accelerated catabolism of corticosteroids.

Methods: A prospective, randomised study comparing adrenal function in 20 patients with pulmonary tuberculosis in the first five days treated with two different antituberculosis regimens, one containing rifampicin, and the other ciprofloxacin.

Results: Demographic, clinical and laboratory results were similar in both groups. Both groups showed a statistically significant and similar decrease in morning cortisol, with similar responses to ACTH stimulation at both 30 and 60 minutes before and after four days of treatment. In the entire cohort, 40% demonstrated an incremental cortisol rise of $<250\text{nmol/l}$ after ACTH stimulation on day 1. Mean basal cortisol concentrations were substantially elevated and DHEA-S levels were consistently subnormal, resulting in a high cortisol:DHEA-S ratio. No patient demonstrated overt adrenal insufficiency. There were no significant differences between the two groups before or during therapy for any electrolytes, hormones or calculated serum osmolality.

Conclusions: Rifampicin did not additionally impair adrenocortical function during the initial period of therapy.

Acknowledgements

I would like to acknowledge and thank my uncomplaining supervisors, Professor Barry Joffe and Professor Charles Feldman, and Dr Vanessa Panz, Professor Derek Raal and Professor Hendrik Koornof, for their constant support and advice, without which I would not have completed this research report. Dr Panz also helped in the preparation, coordination and submission of the publication with an extraordinary degree of perseverance and patience, and I am grateful to her for her gentle words of encouragement. I would like to thank Bayer for donating the ciprofloxacin, and to Ms van den Bergh from the Johannesburg Hospital pharmacy, for arranging the provision of the antituberculous drugs. I would also like to thank the Reproductive Health and HIV Research Unit (under Professor Helen Rees) and the Clinical HIV Research Unit (under Dr Ian Sanne), for the significant amount of time they allowed to me to pursue this project. The Department of Medicine at the University contributed R5000 through a research award to the funding of the study. Finally, I would like to thank the Bruns family and Laura Maxwell-Stewart for giving me their Cape Town homes to write all this up.

Table of contents

Page	Page number
Title page	i
Declaration	ii
Dedication	iii
Publications and presentations arising	iv
Abstract	v
Acknowledgements	vi
Table of contents	vii
List of figures	x
List of tables	xi

1 Introduction

1.1. Overview	1
1.2. Tuberculosis in Southern Africa	1
1.3. TB and mortality in the developing world	2
1.4. Adrenal failure	3
1.4.1. The hypothalamic-pituitary-adrenal (HPA) axis	3
1.4.2. Causes of hypoadrenalism	6
1.4.3. Laboratory evaluation of adrenal function	8
1.5. TB, rifampicin and HPA axis	10
1.5.1. Overview	10

1.5.2. TB and adrenal function	10
1.5.3. Effects of rifampicin on steroid metabolism	14
1.5.4. Clinical cases of hypoadrenalism secondary to rifampicin	15
1.6. Role of rifampicin in treating TB	16
1.7. Rifampicin and the cytochrome systems	17
1.8. Impact and use of quinolones in treating TB	19
1.9. Summary of literature reviews	19
1.10 Background to this study	20
1.11 Aim of this study	20
2 Materials and Methods	21
2.1 Summary:	21
2.1.1 Study population	21
2.1.2 Informed consent	21
2.1.3 Randomisation	22
2.1.4 Baseline data collection	22
2.1.5 Treatment initiation	23
2.1.6 Biochemical and hormone assays	26
2.2 Interpretation of results	26
2.3 Statistical analysis	27

3 Results	28
3.1 Baseline results of participants	28
3.1.1 Clinical characteristics	28
3.1.2 Baseline laboratory data	30
3.1.3 Non-hormonal laboratory values on treatment	35
3.1.5 Hormonal laboratory values on treatment	37
3.1.5 Responses to cosyntropin stimulation testing	39
4 Discussion	43
5 Conclusion	48
6 Appendices:	50
1) South African Medical Journal article	51
2) Conference Poster	56
3) Human Research Ethics Committee approval form	57
7 References	58

List of figures

Figure 1: The HPA axis	5
Figure 2: Recruitment procedure	24
Figure 3: Cortisol responses during stimulation testing	40

List of tables

Table 2: Study procedure post consent	25
Table 3.1: Baseline results: Demographic and clinical	29
Table 3.2: Baseline results: Laboratory	31-34
Table 3.3: Electrolytes and renal function at baseline, day 1, 3 and 5	36
Table 3.4: Serum concentrations of pituitary and adrenal hormones in the two groups of patients during treatment.	38
Table 3.5: Cortisol concentrations during stimulation testing	40
Table 3.6: Rifampicin group: cortisol levels	41
Table 3.7: Ciprofloxacin group: cortisol levels	42